
|Articles|July 1, 2005
Oracea phase 3 clinical trials show 'highly significant' results
Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Quality of Life in CSU Shaped by More Than Skin Symptoms
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














